🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interested in getting involved with ASH? Join us on October 16, 2023 | 2:00 pm EST - we'll chat about involvement at every level - including for trainees! #ASHTrainee Register here: events.bizzabo.com/ASHClinicalNew…

🚨A great thread from David Russler-Germain, MD/PhD on our Blood Journal paper just out, looking at the interaction between polatuzumab efficacy and cell of origin in DLBCL #lymsm #lymphoma Program On Regulation, Therapeutics, And Law Brigham and Women’s Research

Congratulations Schatz Lab member Paola Manara for ASH Abstract Achievement Award. And thanks to ASH for the opportunity to present this exciting work.

Our review on mechanisms of resistance to CAR-T cells in lymphoma is online today: tandfonline.com/doi/full/10.10…

The life of a hematopathologist is full of uncertainty….. 🤷🏻‍♀️ So you know all there is to know about CCUS …. But did you know about TCUS?? #SH23 #hemepath #lymsm

My fav #ASH23 RCT of needle type to prevent post-LP headache: - 68 pts, double-blind 22G cutting v 26G atraumatic needle - significantly less post-LP headache with atraumatic 6.5% (vs 31% with conventional needle!) - no diff in LP success #lymsm #leusm ash.confex.com/ash/2023/webpr…

Enjoying #ASH23 trainee programs. Hit up the #imagebank booth for a fun game with Dr Sanam Loghavi, MD صنم لغوی 🔬🧬 and win heme flashcards!!

Paola Manara 's poster ASH Annual Meeting Sunday. Our exciting project on combination strategies with rocaglates in lymphoma. Thanks to all who stopped by with questions and comments. #ASH23

Discovery of ITP Dr. William Harrington, a heme fellow at WashU, injected a unit blood from an ITP pt into himself. His plt count dropped immediately. He was admitted to the hospital with epistaxis, gingival, and rectal bleeding. 1 week later his plt count returned to normal.

Check out our latest review on bispecifics and CAR-T therapies in DLBCL #OpenAccess journal Blood Cancer Journal Jonathan Schatz MD doi.org/10.1038/s41408…

🔥Just released: our pan-tumor analysis on the not-so-elusive HRAS mutation in solid tumors 🚨 This labor of love was originally presented as a series of posters at ASCO AACR and @ESMO annual meetings in 2022-2023! 📑 Open-access: mdpi.com/2072-6694/16/8… 🌊 Let's dive in!

A lovely evening celebrating our ⁦Sylvester Comprehensive Cancer Center⁩ graduating ⁦⁦Hem-Onc Fellows Network⁩ Mentor & Mentee relationships are a two way street. Grateful for teaching & learning from my amazing mentee ⁦Samuel Kareff, MD, MPH⁩ (who I share w ⁦gilberto lopes⁩ #mentoringmatters

Excited to share our new study of risk of T-cell #lymphomas after #CAR therapy. 1/15 🧵 nejm.org/doi/full/10.10…

Five years after being awarded the prestigious National Cancer Institute (National Cancer Institute) designation, we’ve earned it again. 🙌 As the only NCI-designated center in South Florida, we were recognized for our transformational new programs and initiatives, expanding our impact in our

Another gem of an episode

Tune in to our new episode on management of older adults with Hodgkin Lymphoma with Andrew M. Evens, DO, MBA, MSc! tinyurl.com/bddxzphv Here is a clip on outcomes of older adults in S1826 👇 Eddie Cliff

Happy to share our NatureRevClinOncol paper on BTK inhibitors & degraders in #lymsm #CLL with the participation of outstanding colleagues Taylor Lab UM Danilov Lab Yucai Wang, MD, PhD Meghan Thompson Julio Chavez Michele Skye Montoya Chan Cheah nature.com/articles/s4157…

Updated TRIANGLE data #ASH24: 3-yr FFS data: - ibr (85%) >> ASCT alone (75%) - ASCT+ibr (86%) not superior to ibr (85%) However, 3-yr OS is now significant!⭐ - A+I: 90% - I: 91% - A: 85% Given more tox in A+I arm, BTKi-containing induction + maint without ASCT is new SOC! #lymsm

Academic medicine has arrived in the heart of Downtown Doral! UHealth is proud to open its doors to a state-of-the-art facility designed to provide more than 80,000 residents with unparalleled access to cutting-edge care. 🩺 Learn more 🙌: loom.ly/Z_TpTJg

With mentorship of Juan P. Alderuccio and a multi-institutional effort we investigated the prognosis of circulating lymphoma cells in FL. Key points: - higher count is worse with a new suggested cut-off point - Majority of relapses were POD24 Sylvester Comprehensive Cancer Center Miller Medicine